Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer
Publication in refereed journal

Times Cited
Web of Science13WOS source URL (as at 14/09/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractWhole-genome and transcriptome sequencing were used to discover novel gene fusions in a case of colon cancer. A tumor-specific LACTB2-NCOA2 fusion originating from intra-chromosomal rearrangement of chromosome 8 was identified at both DNA and RNA levels. Unlike conventional oncogenic chimeric proteins, the fusion product lacks functional domain from respective genes, indicative of an amorphic rearrangement. This chimeric LACTB2-NCOA2 transcript was detected in 6 out of 99 (6.1%) colorectal cancer (CRC) cases, where NCOA2 was significantly downregulated. Enforced expression of wild-type NCOA2 but not the LACTB2-NCOA2 fusion protein impaired the pro-tumorigenic phenotypes of CRC cells, whereas knockdown of endogenous NCOA2 in normal colonocytes had opposite effects. Mechanistically, NCOA2 inhibited Wnt/beta-catenin signaling through simultaneously upregulating inhibitors and downregulating stimulators of Wnt/beta-catenin pathway. Collectively, our data supports that NCOA2 is a novel negative growth regulatory gene repressing the Wnt/beta-catenin pathway in CRC, where recurrent fusion with LACTB2 contributes to its disruption.
All Author(s) ListYu J, Wu WKK, Liang Q, Zhang N, He J, Li X, Zhang X, Xu L, Chan MTV, Ng SSM, Sung JJY
Journal nameOncogene
Volume Number35
Issue Number2
PublisherNature Publishing Group: Open Access Hybrid Model Option B
Pages187 - 195
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesBiochemistry & Molecular Biology; Cell Biology; Genetics & Heredity; Oncology

Last updated on 2021-15-09 at 04:28